Factors Influencing Success of Novel Spectacle Lenses for Myopia Control

Overview

Novel spectacle lenses such as DIMS, HAL, CARE, and DOT designs show promise in controlling myopia progression, especially in younger children and those with rapid progression. Treatment success depends on factors including patient age, progression rate, daily wear time, and proper lens fitting.

Background

Myopia control has expanded with the development of novel spectacle lenses designed to slow progression by imposing myopic defocus on the retina. These lenses are currently available overseas but not yet FDA-approved in the U.S. Understanding factors that influence treatment efficacy is critical for optimizing outcomes once these lenses become accessible stateside. Combining spectacle lenses with other interventions like multifocal contact lenses, orthokeratology, or low-dose atropine may enhance control, though further large-scale studies are needed.

Data Highlights

Patients with myopia progression faster than -0.50D per 6 months tend to benefit more from optical interventions. Younger children aged 6 to 8 experience stronger myopia control effects compared to older children. Optimal results require 12 to 14 hours of daily lens wear. Mild side effects such as ghosting and glare may reduce compliance.

Key Findings

• Faster progressing myopes (> -0.50D/6 months) show greater benefit from novel spectacle lenses.
• Children aged 6 to 8 have stronger myopia control effects than older children.
• At least 12 to 14 hours of daily wear is necessary for optimal efficacy.
• Proper frame fitting is critical to ensure sufficient retinal myopia-control signals.
• Mild visual side effects (ghosting, glare, reduced contrast) can impact compliance.
• Combining spectacle lenses with orthokeratology or low-dose atropine may have synergistic effects, pending further research.

Clinical Implications

Clinicians should consider patient age and progression rate when recommending novel spectacle lenses for myopia control. Emphasizing consistent daily wear and proper frame fitting can maximize treatment benefits. Monitoring for mild visual disturbances and advising on complementary lifestyle modifications such as increased outdoor time may improve adherence and outcomes.

Conclusion

Novel spectacle lenses represent a promising, non-invasive option for myopia control with efficacy influenced by patient and treatment factors. U.S. optometrists are well-positioned to integrate these lenses into practice upon FDA approval, while remaining vigilant about long-term safety and functional impacts.

References

1. Yuval C et al. 2024 -- Evaluating the Effect of a Myopia Control Spectacle Lens Among Children in Israel: 12-Month Results
2. Yang Y et al. 2025 -- Synergistic efficacy of orthokeratology and 0.01% atropine in controlling pediatric myopia progression